05.04.2012 - Swedish pharma company Astra Zeneca plus Wallenberg Foundation and Swedish government pledge a record investment into the biotech industry.
Stockholm – Under a new initiative, AstraZeneca will invest €2.3m to €4.5m (SEK20m to SEK40m) a year over the next five years in early-stage research projects. The Wallenberg Foundation, a private financing institution which is dedicated to promoting scientific research and education in Sweden, will provide additional €25m (SEK220m). The money will be used to build up technology laboratories for the SciLifeLab collaboration between four Swedish universities. The contribution of the Swedish government is yet unknown, but a spokesperson already announced the government is planning a record investment in the country's life science infrastructure. The details would be published in the autumn budget. Jan Björklund, the Swedish Minister for Education, announced the SciLifeLab will become a national research institute for major research in molecular biosciences and bioinformatics. According to the government’s plan, SciLifeLab will grow to employ about 1,000 scientists and have a turnover of about €113m (SEK1bn) within a few years.SciLifeLab is a joint venture between four universities; Karolinska Institutet, the Royal Institute of Technology, Stockholm University and Uppsala University. The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress. The vision is to make SciLifeLab a competitive centre for high-throughput biosciences with platforms in genomics, comparative genetics, proteomics, bioimaging and functional genomics as well as research communities in biology, medicine and environmental sciences.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more